WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

WMT

130

-1.57%↓

COST

1,011.08

-0.32%↓

PEP

155.5

-0.17%↓

TGT

128.95

-0.98%↓

67.35

-2.5%↓

Home・Akcijų sąrašas・Compass Pathways Plc ADR

Compass Pathways Plc ADR

Uždarymo kaina

9.56 4.82

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.35

Max

9.56

Pagrindiniai rodikliai
By Trading Economics
Pajamos	44M -94M
Darbuotojai	156
EBITDA	91M -46M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+127.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	670M 1.3B
Ankstesnė atidarymo kaina	4.74
Ankstesnė uždarymo kaina	9.56

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

3.645 / 4.0539 Palaikymas ir pasipriešinimas

Compass Pathways Plc ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 19:19; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Group Rejects EQT's Revised Offer

2026-04-24 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Scoring the Cook Era -- Barrons.com

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:09; UTC

Uždarbis

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026-04-24 19:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026-04-24 19:22; UTC

Uždarbis

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026-04-24 19:06; UTC

Uždarbis

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026-04-24 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026-04-24 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026-04-24 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Rejects Revised EQT Offer

2026-04-24 18:12; UTC

Rinkos pokalbiai

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026-04-24 18:06; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026-04-24 17:42; UTC

Uždarbis

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026-04-24 17:28; UTC

Uždarbis

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

2026-04-24 17:28; UTC

Rinkos pokalbiai

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

2026-04-24 17:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-24 17:11; UTC

Rinkos pokalbiai

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

2026-04-24 17:09; UTC

Rinkos pokalbiai

Uždarbis

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

2026-04-24 17:09; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 17:06; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

2026-04-24 16:51; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

2026-04-24 16:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-24 16:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 16:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-04-24 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Compass Pathways Plc ADR Prognozė

Kainos tikslas

By TipRanks

127.87% į viršų

12 mėnesių prognozė

Vidutinis 21.83 USD 127.87%

Aukščiausias 70 USD

Žemiausias 8 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compass Pathways Plc ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Compass Pathways Plc ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.645 / 4.0539Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.